How does the 'Batch-of-One' model change the PAT landscape?

Personalized medicines, such as CAR-T therapies, represent a paradigm shift: the patient is the batch. In this scenario, there is no room for error, and no material to waste on traditional testing. PAT tools must be non-destructive and capable of monitoring very small volumes. The ability to monitor cell viability and phenotype in real-time within the closed-system manufacturing environment is the only way to ensure patient safety.

How is Personalized Medicine PAT Implementation evolving?

The logistical challenges of decentralized manufacturing (at the hospital or bedside) are significant. Monitoring Personalized Medicine PAT Implementation provides insights into how "Lab-on-a-Chip" technologies are being integrated into automated bedside manufacturing units. In 2024, the focus is on developing robust, plug-and-play sensors that can be operated by medical staff rather than specialized analytical chemists.

Is PAT the key to lowering the cost of CAR-T therapies?

Currently, the high cost of cell therapies is largely due to the manual labor and high failure rates associated with production. Automating these processes using PAT could potentially lower the cost of a single treatment by 50% or more by 2025, making these life-saving therapies accessible to a much wider patient population.

  Cloud-based MVDA

Technology

Application in CGT

Strategic Benefit

Micro-Raman

Metabolite sensing in small-scale bags

Non-invasive monitoring

Bio-Capacitance

Live cell density measurement

Precise harvesting timing

Centralized monitoring of remote sites

Unified quality standards

  

2025 Clinical Outlook

By late 2025, we anticipate the first regulatory approval for an automated, PAT-controlled cell manufacturing platform that does not require final sterile testing before infusion.

Author: Sofiya Sanjay

Designation: Healthcare Research Consultant, Market Research Future

About: At Market Research Future (MRFR), we enable organizations to unravel complex industries through Cooked Research Reports (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services. Our studies across products, technologies, applications, end users, and global to country-level segments help decision-makers see more, know more, and do more.

Contact: 99 Hudson Street, 5th Floor, New York, NY 10013, USA | (855) 661-4441 (US) | +44 1720 412 167 (UK) | +91 2269738890 (APAC) | info@marketresearchfuture.com